Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/35394
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPolkinghorne K.R.en
dc.contributor.authorKerr P.G.en
dc.contributor.authorChoo S.Z.en
dc.date.accessioned2021-05-14T11:57:27Zen
dc.date.available2021-05-14T11:57:27Zen
dc.date.copyright2019en
dc.date.created20200305en
dc.date.issued2020-03-05en
dc.identifier.citationNephrology. 24 (5) (pp 542-549), 2019. Date of Publication: 01 May 2019.en
dc.identifier.issn1320-5358en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/35394en
dc.description.abstractAim: Extended-hours haemodialysis has long been regarded as the optimal form of dialysis for solute clearance. With emerging benefits of haemodiafiltration, we wanted to compare these two head-to-head. Method(s): In this randomized cross-over trial, we recruited existing nocturnal haemodialysis patients, who had not been hospitalized in the prior 3 months. After a baseline 8 h haemodialysis session, subjects were randomized to either 2 weeks of 8 h haemodialysis or 4 h haemodiafiltration with cross-over to the alternative treatment after a 2-week washout period. Subjects were additionally randomized to the Fresenius FX80 or Nipro Elisio in a parallel design. Blood and dialysate samples were collected at baseline and at the end of both study periods. Result(s): Twelve patients completed the study. Mean (SD) age and body mass index were 55.1 +/- 11.5 years and 36.4 +/- 10.8, respectively. Urea and creatinine reduction ratios were higher with extended-hours haemodialysis compared to haemodiafiltration (difference 14.0%, 95% CI = 10.6, 17.3; P < 0.001 and 9.1%, 95% CI = 11.0, 7.2; P < 0.001). Fibroblast growth factor 23 (FGF23) clearance was superior with haemodiafiltration (difference 20.1%, 95% CI = 8.7, 31.6; P = 0.001). No difference was seen in reduction ratios for phosphate, retinol binding protein, alpha-1-microglobulin, beta-2-microglobulin and fetuin with both modalities. Compared to Nipro Elisio, Fresenius FX80 dialyser achieved higher beta-2-microglobulin clearance (Period 1: difference 7.8%, 95% CI = 1.3, 14.4; P = 0.02, Period 2:7.5%, 95% CI = 1.0, 14.1; P = 0.02). Conclusion(s): Small solute clearance was superior with extended-hours haemodialysis while haemodiafiltration enhanced FGF23 clearance. Beta-2-microglobulin clearance was improved with Fresenius FX80 dialyser, but this difference is unlikely to be clinically significant.Copyright © 2018 Asian Pacific Society of Nephrologyen
dc.languageEnglishen
dc.languageenen
dc.publisherBlackwell Publishingen
dc.relation.ispartofNephrologyen
dc.subject.meshcreatinine blood level-
dc.subject.meshcrossover procedure-
dc.subject.meshhemodiafiltration-
dc.subject.meshhemodialysis-
dc.subject.meshhospitalization-
dc.subject.meshintermethod comparison-
dc.subject.meshpilot study-
dc.subject.meshalpha 1 microglobulin-
dc.subject.meshbeta 2 microglobulin-
dc.subject.meshcreatinine-
dc.subject.meshfetuin-
dc.subject.meshfibroblast growth factor 23-
dc.subject.meshretinol binding protein-
dc.subject.meshdialysate-
dc.subject.meshdialyzer-
dc.subject.meshFresenius FX80-
dc.subject.meshNipro Elisio-
dc.titleBiochemical comparison of 8 h haemodialysis and 4 h haemodiafiltration, and two dialysis membranes, in a randomized cross-over trial.en
dc.typeArticleen
dc.identifier.affiliationNephrology-
dc.type.studyortrialRandomised controlled trial-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/nep.13397-
dc.publisher.placeAustraliaen
dc.identifier.pubmedid29722110 [http://www.ncbi.nlm.nih.gov/pubmed/?term=29722110]en
dc.identifier.source2004316230en
dc.identifier.institution(Choo, Polkinghorne, Kerr) Department of Nephrology, Monash Health, Clayton, VIC, Australia (Polkinghorne, Kerr) Department of Medicine, Monash University, Clayton, VIC, Australia (Polkinghorne) School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australiaen
dc.description.addressS.Z. Choo, Department of Nephrology, Monash Health, Clayton, VIC, Australia. E-mail: shizhou.choo@monashhealth.orgen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2020 Elsevier B.V., All rights reserved.en
dc.subect.keywordsbeta 2-microglobulin fibroblast growth factors hemodiafiltration renal dialysis uraemic toxinsen
dc.identifier.authoremailChoo S.Z.; shizhou.choo@monashhealth.orgen
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairetypeArticle-
crisitem.author.deptNephrology-
crisitem.author.deptNephrology-
Appears in Collections:Articles
Show simple item record

Page view(s)

44
checked on Sep 13, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.